JP2025511402A5 - - Google Patents
Info
- Publication number
- JP2025511402A5 JP2025511402A5 JP2024559035A JP2024559035A JP2025511402A5 JP 2025511402 A5 JP2025511402 A5 JP 2025511402A5 JP 2024559035 A JP2024559035 A JP 2024559035A JP 2024559035 A JP2024559035 A JP 2024559035A JP 2025511402 A5 JP2025511402 A5 JP 2025511402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- azd5305
- prostate cancer
- enzalutamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362613P | 2022-04-07 | 2022-04-07 | |
| US63/362,613 | 2022-04-07 | ||
| PCT/EP2023/059130 WO2023194530A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511402A JP2025511402A (ja) | 2025-04-15 |
| JP2025511402A5 true JP2025511402A5 (https=) | 2026-04-10 |
Family
ID=86226547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559035A Pending JP2025511402A (ja) | 2022-04-07 | 2023-04-06 | 癌を治療するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250213556A1 (https=) |
| EP (1) | EP4504182A1 (https=) |
| JP (1) | JP2025511402A (https=) |
| KR (1) | KR20240170957A (https=) |
| CN (1) | CN119212702A (https=) |
| AU (1) | AU2023250031A1 (https=) |
| CA (1) | CA3254949A1 (https=) |
| IL (1) | IL316017A (https=) |
| MX (1) | MX2024012392A (https=) |
| TW (1) | TW202404661A (https=) |
| WO (1) | WO2023194530A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600137A (zh) * | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
-
2023
- 2023-04-06 US US18/853,504 patent/US20250213556A1/en active Pending
- 2023-04-06 WO PCT/EP2023/059130 patent/WO2023194530A1/en not_active Ceased
- 2023-04-06 CN CN202380032432.8A patent/CN119212702A/zh active Pending
- 2023-04-06 AU AU2023250031A patent/AU2023250031A1/en active Pending
- 2023-04-06 JP JP2024559035A patent/JP2025511402A/ja active Pending
- 2023-04-06 IL IL316017A patent/IL316017A/en unknown
- 2023-04-06 EP EP23719651.4A patent/EP4504182A1/en active Pending
- 2023-04-06 CA CA3254949A patent/CA3254949A1/en active Pending
- 2023-04-06 KR KR1020247036944A patent/KR20240170957A/ko active Pending
- 2023-04-07 TW TW112113000A patent/TW202404661A/zh unknown
-
2024
- 2024-10-04 MX MX2024012392A patent/MX2024012392A/es unknown